Literature DB >> 23949905

Six-month intragastric balloon treatment for obesity improves lung function, body composition, and metabolic syndrome.

Thiago Thomaz Mafort1, Eduardo Madeira, Miguel Madeira, Erika Paniago Guedes, Rodrigo Oliveira Moreira, Laura Maria Carvalho de Mendonça, Maria Lucia Fleiuss Farias, Agnaldo José Lopes.   

Abstract

BACKGROUND: The purpose of this study is to establish whether the use of an intragastric balloon (IGB) for 6 months improves lung function, metabolic parameters, and body fat distribution in patients with overweight/obesity and metabolic syndrome (MS).
METHODS: This is a longitudinal and interventional study on 40 adults, whose anthropometric, laboratory, and lung function parameters were assessed and who underwent dual-energy X-ray absorptiometry (DXA) before implantation and after removal of IGB.
RESULTS: The total lung capacity (TLC) (p = 0.0001), functional residual capacity (FRC) (p = 0.0001), residual volume (p = 0.0005), and expiratory reserve volume (ERV) (p = 0.0001) were significantly reduced by IGB. The body mass index (BMI) significantly decreased from a median of 39.1 kg/m(2) at the beginning of the study to 34.5 kg/m(2) at the end of the 6-month period (p = 0.0001). At the end of the study, 31 participants (77.5%) no longer met the diagnostic criteria of MS. The percentage of truncal, android, gynoid, and total fat investigated by DXA exhibited significant reductions (p = 0.0001). Significant correlations were found between delta TLC and delta waist circumference (ρ = -0.34; p = 0.03), delta FRC and delta IMC (ρ = -0.39; p = 0.01), delta ERV and delta BMI (ρ = -0.44; p = 0.005), and delta ERV and delta high-density lipoprotein (HDL) (ρ = -0.37; p = 0.02). Significant correlations were also found between delta ERV and delta truncal (ρ = -0.51; p = 0.004), android (ρ = -0.46; p = 0.01), gynoid (ρ = -0.55; p = 0.001), and total fat (ρ = -0.59; p = 0.0005).
CONCLUSIONS: IGB efficiently induced weight loss and promoted the improvement of lung function parameters, with a reduction of the restrictive ventilatory defect. It also promoted improvements of MS and the pattern of body fat distribution.

Entities:  

Mesh:

Year:  2014        PMID: 23949905     DOI: 10.1007/s11695-013-1061-5

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  42 in total

1.  Reference values for lung function tests. I. Static volumes.

Authors:  J A Neder; S Andreoni; A Castelo-Filho; L E Nery
Journal:  Braz J Med Biol Res       Date:  1999-06       Impact factor: 2.590

2.  Body fat distribution, body composition, and respiratory function in elderly men.

Authors:  S Goya Wannamethee; A Gerald Shaper; Peter H Whincup
Journal:  Am J Clin Nutr       Date:  2005-11       Impact factor: 7.045

Review 3.  Dual-energy X-ray absorptiometry and body composition.

Authors:  Lindsay D Plank
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2005-05       Impact factor: 4.294

Review 4.  Evidence-based review of the Bioenterics intragastric balloon for weight loss.

Authors:  Jean-Marc Dumonceau
Journal:  Obes Surg       Date:  2008-06-21       Impact factor: 4.129

5.  The weight of obesity on lung health.

Authors:  Anne E Dixon; Lennart K A Lundblad; Benjamin T Suratt
Journal:  Pulm Pharmacol Ther       Date:  2013-03-30       Impact factor: 3.410

6.  Pulmonary function and abdominal adiposity in the general population.

Authors:  Heather M Ochs-Balcom; Brydon J B Grant; Paola Muti; Christopher T Sempos; Jo L Freudenheim; Maurizio Trevisan; Patricia A Cassano; Licia Iacoviello; Holger J Schünemann
Journal:  Chest       Date:  2006-04       Impact factor: 9.410

7.  BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons.

Authors:  Gontrand Lopez-Nava; Miguel Angel Rubio; Susana Prados; Gabriela Pastor; Mar Rodriguez Cruz; Ena Companioni; Andres Lopez
Journal:  Obes Surg       Date:  2010-03-20       Impact factor: 4.129

8.  Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients.

Authors:  Rosario Forlano; Antonio Massimo Ippolito; Angelo Iacobellis; Antonio Merla; Maria Rosa Valvano; Grazia Niro; Vito Annese; Angelo Andriulli
Journal:  Gastrointest Endosc       Date:  2009-10-27       Impact factor: 9.427

Review 9.  Androgens and body fat distribution.

Authors:  Karine Blouin; Ariane Boivin; André Tchernof
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-07       Impact factor: 4.292

10.  Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis.

Authors:  Nicola Crea; Giacomo Pata; Domenico Della Casa; Luigi Minelli; Giovanni Maifredi; Ernesto Di Betta; Francesco Mittempergher
Journal:  Obes Surg       Date:  2009-06-09       Impact factor: 4.129

View more
  11 in total

1.  Changes in Body Adiposity, Dietary Intake, Physical Activity and Quality of Life of Obese Individuals Submitted to Intragastric Balloon Therapy for 6 Months.

Authors:  Marcella Rodrigues Guedes; Ricardo José Fittipaldi-Fernandez; Cristina Fajardo Diestel; Márcia Regina Simas Torres Klein
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

Review 2.  Filling the Void: A Review of Intragastric Balloons for Obesity.

Authors:  Patrick Laing; Tuan Pham; Linda Jo Taylor; John Fang
Journal:  Dig Dis Sci       Date:  2017-04-18       Impact factor: 3.199

3.  Impact of Intragastric Balloon Treatment on Adipokines, Cytokines, and Metabolic Profile in Obese Individuals.

Authors:  Marcella Rodrigues Guedes; Ricardo José Fittipaldi-Fernandez; Cristina Fajardo Diestel; Márcia Regina Simas Torres Klein
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

Review 4.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

Review 5.  The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis.

Authors:  Violeta B Popov; Amy Ou; Allison R Schulman; Christopher C Thompson
Journal:  Am J Gastroenterol       Date:  2017-01-24       Impact factor: 10.864

6.  Impact of Intragastric Balloon Before Laparoscopic Gastric Bypass on Patients with Super Obesity: a Randomized Multicenter Study.

Authors:  B Coffin; V Maunoury; F Pattou; X Hébuterne; S Schneider; M Coupaye; S Ledoux; F Iglicki; F Mion; M Robert; E Disse; J Escourrou; G Tuyeras; Y Le Roux; C Arvieux; P Pouderoux; N Huten; T Alfaiate; D Hajage; S Msika
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

7.  Safety and Effectiveness of an Intragastric Balloon as an Adjunct to Weight Reduction in a Post-Marketing Clinical Setting.

Authors:  Rachel L Moore; Laura Eaton; Julie Ellner
Journal:  Obes Surg       Date:  2020-11       Impact factor: 4.129

Review 8.  Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function.

Authors:  Thiago Thomaz Mafort; Rogério Rufino; Cláudia Henrique Costa; Agnaldo José Lopes
Journal:  Multidiscip Respir Med       Date:  2016-07-12

9.  Impact of a 6-month treatment with intragastric balloon on body composition and psychopathological profile in obese individuals with metabolic syndrome.

Authors:  Erika P Guedes; Eduardo Madeira; Thiago T Mafort; Miguel Madeira; Rodrigo O Moreira; Laura Maria C Mendonça; Amélio F Godoy-Matos; Agnaldo J Lopes; Maria Lucia F Farias
Journal:  Diabetol Metab Syndr       Date:  2016-12-19       Impact factor: 3.320

10.  Intragastric Balloon for Overweight Patients.

Authors:  Flavio Augusto Martins Fernandes; Gustavo L Carvalho; Diego L Lima; Prashanth Rao; Phillip P Shadduck; Isabelle D Montandon; Juscielle de Souza Barros; Ingrid Lais Vieira Rodrigues
Journal:  JSLS       Date:  2016 Jan-Mar       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.